| 1 |
35278141 | Correction to: Targeted therapy with anlotinib for a H3K27M-mutant diffuse midline glioma patient with PDGFR‑α mutation: a case report. | 2022 Mar 12 |
1 |
| 2 |
35513832 | Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy. | 2022 May 6 |
1 |
| 3 |
32949176 | Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma. | 2021 Mar |
1 |
| 4 |
33740528 | A small molecular multi-targeting tyrosine kinase inhibitor, anlotinib, inhibits pathological ocular neovascularization. | 2021 Jun |
1 |
| 5 |
34434895 | An Integrative Metabolomic and Network Pharmacology Study Revealing the Regulating Properties of Xihuang Pill That Improves Anlotinib Effects in Lung Cancer. | 2021 |
1 |
| 6 |
34812950 | Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report. | 2021 Nov 23 |
1 |
| 7 |
32266457 | A phase I study investigation of metabolism, and disposition of [14C]-anlotinib after an oral administration in patients with advanced refractory solid tumors. | 2020 May |
1 |
| 8 |
32587778 | Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling. | 2020 May 15 |
1 |
| 9 |
32724339 | Anlotinib as a molecular targeted therapy for tumors. | 2020 Aug |
2 |
| 10 |
27716285 | Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. | 2016 Oct 4 |
1 |